These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 2907022)

  • 1. Oesophageal transit of small tablets.
    Robertson CS; Hardy JG
    J Pharm Pharmacol; 1988 Aug; 40(8):595-6. PubMed ID: 2907022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrointestinal scintigraphy with 99mTc-DTPA labeled tablets in fed and fasting subjects.
    Maublant JC; Sournac M; Aiache JM; Veyre A
    Eur J Nucl Med; 1989; 15(3):143-5. PubMed ID: 2653832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of colonic transit of nondisintegrating tablets in healthy subjects.
    Price JM; Davis SS; Wilding IR
    Dig Dis Sci; 1993 Jun; 38(6):1015-21. PubMed ID: 8389686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combined analysis by ultrasonography and scintigraphy of a tablet along the digestive tract. Preliminary study with 4 cases].
    Maublant J; Dapony M; Sournac M; Goutay E; Hassine H; Aiache JM; Veyre A
    Ann Radiol (Paris); 1987; 30(6):410-2. PubMed ID: 3329486
    [No Abstract]   [Full Text] [Related]  

  • 5. Impaired oesophageal transit of capsule versus tablet formulations in the elderly.
    Perkins AC; Wilson CG; Blackshaw PE; Vincent RM; Dansereau RJ; Juhlin KD; Bekker PJ; Spiller RC
    Gut; 1994 Oct; 35(10):1363-7. PubMed ID: 7959187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reproducibility of oesophageal transit studies: several 'single swallows' must be performed.
    Bartlett RJ; Parkin A; Ware FW; Riley A; Robinson PJ
    Nucl Med Commun; 1987 May; 8(5):317-26. PubMed ID: 3317159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects.
    Perkins AC; Blackshaw PE; Hay PD; Lawes SC; Atherton CT; Dansereau RJ; Wagner LK; Schnell DJ; Spiller RC
    Clin Ther; 2008 May; 30(5):834-44. PubMed ID: 18555931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A scintigraphic study of local oesophageal bolus transit: differences between patients with Barrett's oesophagus and healthy controls.
    Stier AW; Stein HJ; Allescher HD; Feith M; Schwaiger M
    Gut; 2002 Feb; 50(2):159-64. PubMed ID: 11788553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissolution rate and transit times of technetium-99m DTPA-labeled tablets.
    Maublant JC; Sournac M; Aiache JM; Veyre A
    J Nucl Med; 1987 Jul; 28(7):1199-203. PubMed ID: 3298574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastrointestinal transit of model mini-tablet controlled release oral dosage forms in fasted human volunteers.
    Podczeck F; Course N; Newton JM; Short MB
    J Pharm Pharmacol; 2007 Jul; 59(7):941-5. PubMed ID: 17637188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of size and shape of tablets on their esophageal transit.
    Channer KS; Virjee JP
    J Clin Pharmacol; 1986 Feb; 26(2):141-6. PubMed ID: 3950057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meal-induced acceleration of tablet transit through the human small intestine.
    Fadda HM; McConnell EL; Short MD; Basit AW
    Pharm Res; 2009 Feb; 26(2):356-60. PubMed ID: 18982248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive radionuclide esophagogastrointestinal transit study: methodology, reference values, and initial clinical experience.
    Antoniou AJ; Raja S; El-Khouli R; Mena E; Lodge MA; Wahl RL; Clarke JO; Pasricha P; Ziessman HA
    J Nucl Med; 2015 May; 56(5):721-7. PubMed ID: 25766893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Esophageal transit of the weekly film-coated risedronate (Actonel) placebo tablet in subjects with Kyphosis.
    Perkins AC; Frier M; Blackshaw PE; Spiller RC; Fairbairn KJ; Dansereau RJ; Kinghorn T; San P; Hosking D
    Int J Pharm; 2006 Mar; 311(1-2):20-5. PubMed ID: 16431045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oesophageal transit of six commonly used tablets and capsules.
    Hey H; Jørgensen F; Sørensen K; Hasselbalch H; Wamberg T
    Br Med J (Clin Res Ed); 1982 Dec; 285(6356):1717-9. PubMed ID: 6816343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of formulation on oesophageal transit.
    Channer KS; Virjee JP
    J Pharm Pharmacol; 1985 Feb; 37(2):126-9. PubMed ID: 2858546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of esophageal transit of tablets and capsules in 30 cats.
    Westfall DS; Twedt DC; Steyn PF; Oberhauser EB; VanCleave JW
    J Vet Intern Med; 2001; 15(5):467-70. PubMed ID: 11596734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between oesophageal dysmotility and cardiovascular autonomic dysfunction in diabetic patients without gastrointestinal symptoms of autonomic neuropathy.
    Jermendy G; Fornet B; Koltai MZ; Pogátsa G
    Diabetes Res; 1991 Apr; 16(4):193-7. PubMed ID: 1802487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormalities in the duodenal transit and motility in duodenal ulcer patients: studies with a new isotopic technique.
    Quon MG; Mena I; Valenzuela JE
    Gut; 1989 May; 30(5):579-85. PubMed ID: 2659441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of gamma scintigraphy to follow the gastrointestinal transit of pharmaceutical formulations.
    Christensen FN; Davis SS; Hardy JG; Taylor MJ; Whalley DR; Wilson CG
    J Pharm Pharmacol; 1985 Feb; 37(2):91-5. PubMed ID: 2858556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.